Your account is not claimed yet. You can sign up with ORCID to claim your account.

Sarina A Piha-Paul (Sarina Piha-Paul)

Scopus Author ID Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 15

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

Investigational new drugs

Journal for immunotherapy of cancer

International journal of cancer

University of Texas MD Anderson Cancer Center

Louisiana State University Health Sciences Center (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Texas MD Anderson Cancer Center

United States

Associate Professor, Medical Oncology :: Department of Investigational Cancer Therapeutics

Education History

Louisiana State University Health Sciences Center

United States

PHD

Publications

Timothy P DiPeri, Kathleen Kong, Kaushik Varadarajan, Daniel D Karp, Jaffer A Ajani, Shubham Pant, Michael F Press, Sarina A Piha-Paul, Ecaterina E Dumbrava, Funda Meric-Bernstam
Discordance of HER2 Expression and/or Amplification on Repeat Testing. Molecular cancer therapeutics (2023)
Roberto Carmagnani Pestana, Justin Tyler Moyers, Jason Roszik, Shiraj Sen, David S Hong, Aung Naing, Cynthia E Herzog, Siqing Fu, Sarina A Piha-Paul, Jordi Rodon Ahnert, Timothy Anthony Yap, Daniel D Karp, Apostolia-Maria Tsimberidou, Shubham Pant, Maria Alejandra Zarzour, Ravin Ratan, Vinod Ravi, Robert S Benjamin, Alexander J F Lazar, Wei-Lien Wang, Najat C Daw, Jonathan D Gill, Douglas J Harrison, Valerae O Lewis, Christina Lynn Roland, Shreyaskumar R Patel, Jonathan A Livingston, Neeta Somaiah, Joseph A Ludwig, Anthony P Conley, Nelson Hammerschlak, Richard G Gorlick, Funda Meric-Bernstam, Vivek Subbiah
Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101). Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Blessie Elizabeth Nelson, Apostolia M Tsimberidou, Xueyao Fu, Siqing Fu, Vivek Subbiah, Anil K Sood, Jordi Rodon, Daniel D Karp, George Blumenschein, Edmund S Kopetz, Shubham Pant, Sarina A Piha-Paul
A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors. The oncologist (2023)
Jason John Luke, Sarina A Piha-Paul, Theresa M Medina, Claire F Verschraegen, Mary Varterasian, Aoife M Brennan, Richard J Riese, Anna Sokolovska, James F Strauss, David L Hava, Filip Janku
Phase I study of SYNB1891, an engineered E coli Nissle strain expressing STING agonist, with and without atezolizumab in advanced malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Jason John Luke, Sarina A Piha-Paul, Theresa M Medina, Claire F Verschraegen, Mary Varterasian, Aoife M Brennan, Richard J Riese, Anna Sokolovska, James F Strauss, David L Hava, Filip Janku
Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Sarina A Piha-Paul, Chieh Tseng, Hai T Tran, Meng Gao, Daniel D Karp, Vivek Subbiah, Apostolia Maria Tsimberidou, Jitesh D Kawedia, Siqing Fu, Shubham Pant, Timothy A Yap, Van K Morris, Bryan K Kee, Mariela Blum Murphy, JoAnn Lim, Funda Meric-Bernstam
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation. Cancer chemotherapy and pharmacology (2023)
Justin Tyler Moyers, Roberto Carmagnani Pestana, Jason Roszik, David S Hong, Aung Naing, Siqing Fu, Sarina A Piha-Paul, Timothy Anthony Yap, Daniel D Karp, Jordi Rodon Ahnert, Jonathan A Livingston, Maria Alejandra Zarzour, Vinod Ravi, Shreyaskumar R Patel, Robert S Benjamin, Joseph A Ludwig, Cynthia E Herzog, Ravin Ratan, Neeta Somaiah, Anthony P Conley, Richard G Gorlick, Funda Meric-Bernstam, Vivek Subbiah
Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102). Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Kanwal P Raghav, Bettzy Stephen, Daniel D Karp, Sarina A Piha-Paul, David S Hong, Dipti Jain, Dilichukwu O Chudy Onwugaje, Abdulrahman Abonofal, Anneleis F Willett, Michael Overman, Brandon Smaglo, Ryan W Huey, Funda Meric-Bernstam, Gauri R Varadhachary, Aung Naing
Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial. Journal for immunotherapy of cancer 10 (5) (2022)
Sarina A Piha-Paul, Ravit Geva, Tira J Tan, Darren Wt Lim, Cinta Hierro, Toshikiko Doi, Osama Rahma, Alexander Lesokhin, Jason John Luke, Javier Otero, Lisa Nardi, Angad Singh, Alexandros Xyrafas, Xinhui Chen, Jennifer Mataraza, Philippe L Bedard
First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas. Journal for immunotherapy of cancer 9 (8) (2022)
Sophie Cousin, Jean Yves Blay, Irene Braña Garcia, Johann S de Bono, Christophe Le Tourneau, Victor Moreno, Jose Trigo, Christine L Hann, Arun A Azad, Seock-Ah Im, Philippe A Cassier, Christopher A French, Antoine Italiano, Vicki L Keedy, Ruth Plummer, Marie-Paule Sablin, Matthew L Hemming, Geraldine Ferron-Brady, Anastasia Wyce, Ahmed Khaled, Antara Datta, Shawn W Foley, Michael T McCabe, Yuehui Wu, Thierry Horner, Brandon E Kremer, Arindam Dhar, Peter J O'Dwyer, Geoffrey I Shapiro, Sarina A Piha-Paul
Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein of the testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study. International journal of cancer (2021)
Sarina A Piha-Paul, Analía Azaro, Hendrik Tobias Arkenau, Do-Youn Oh, Matthew D Galsky, Sumanta Kumar Pal, Kensuke Hamada, Yaohua He, Ikuo Yamamiya, Karim A Benhadji, Antoine Hollebecque
A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations. Investigational new drugs 39 (5) (2021)
Sarina A Piha-Paul, Kyaw Z Thein, Paul De Souza, Richard Kefford, Tara Gangadhar, Christopher Smith, Shelly Schuster, William C Zamboni, Claire E Dees, Ben Markman
First-in-human, phase I/IIa study of CRLX301, a nanoparticle drug conjugate containing docetaxel, in patients with advanced or metastatic solid malignancies. Investigational new drugs 39 (4) (2021)
Sarina A Piha-Paul, Ecaterina E Dumbrava, Binoj C Nair, Wendy Xiong, Li Xu, Rosa Mostorino, Vivek Subbiah, Nizar Tannir, Siqing Fu, Aung Naing, Filip Janku, Daniel D Karp, Shreyaskumar Patel, Najat C Daw, David Hong, Funda Meric-Bernstam, Ralph Zinner
A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies. OncoTargets and therapy 14 (2021)
Sarina A Piha-Paul, Do-Youn Oh, Makoto Ueno, David Malka, Hyun Cheol Chung, Adnan Nagrial, Robin K Kelley, Willeke Ros, Antoine Italiano, Kazuhiko Nakagawa, Hope S Rugo, Filippo de Braud, Andrea Iolanda Varga, Aaron Hansen, Hui Wang, Suba Krishnan, Kevin G Norwood, Toshihiko Doi
Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies. International journal of cancer 147 (8) (2020)
Goldy C George, Eucharia C Iwuanyanwu, Adrianna S Buford, Sarina A Piha-Paul, Vivek Subbiah, Siqing Fu, Daniel D Karp, Shubham Pant, Christina O Hinojosa, Kenneth R Hess, Charles S Cleeland, Elmer V Bernstam, Funda Meric-Bernstam, David S Hong
Cancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational Study. Journal of medical Internet research 21 (3) (2019)

Sarina A Piha-Paul.css-eqlu8i{font-size:small;padding-left:4px;} (Sarina Piha-Paul)

Publication Activity (10 Years)

Top Topics

Top Venues

Sarina A Piha-Paul (Sarina Piha-Paul)